NCT04631744 2025-12-18
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Completed
Clinical Trials
11 trialsNCT05265988 2024-07-31
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT01630590 2022-03-25
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01812668 2021-08-05
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01588821 2020-09-29
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Phase 2 Completed
NCT01599793 2020-03-26
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
Phase 2 Completed
NCT01683994 2019-11-08
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01605227 2018-03-14
COMET-1
Exelixis
Phase 3 Completed
NCT01347788 2016-11-28
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Massachusetts General Hospital
Phase 1 Completed